Tecovirimat

Tecovirimat

SCHEMBL14601849

O=C(NN1C(=O)[C@@H]2C3C=CC([C@H]4C[C@@H]34)[C@@H]2C1=O)c1ccc(C(F)(F)F)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPG057

The experimentally established mechanism targets of Tecovirimat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.73
SMN1; SMN2 Q16637 2/20 0.73
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
GAA P10253 2/20 0.49
MAPT P10636 3/20 0.46
LMNA P02545 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HTT P42858 2/20 0.46
MAPK1 P28482 1/20 0.46
THRB P10828 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tecovirimat SCHEMBL404303 1.00 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2MEN1KMT2AGAA
Tecovirimat SCHEMBL16177619 1.00 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2MEN1KMT2AGAA
Tecovirimat SCHEMBL16177983 1.00 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2MEN1KMT2AGAA
Tecovirimat SCHEMBL404743 1.00 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2MEN1KMT2AGAA
Tecovirimat SCHEMBL20126651 1.00 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2MEN1KMT2AGAA
Tecovirimat SCHEMBL10034023 1.00 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2MEN1KMT2AGAA
Tecovirimat SCHEMBL10029251 1.00 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2MEN1KMT2AGAA
Tecovirimat SCHEMBL406595 1.00 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2MEN1KMT2AGAA
Tecovirimat SCHEMBL21549158 1.00 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2MEN1KMT2AGAA
Tecovirimat SCHEMBL30702765 0.99 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10029985-B2 Methods of preparing Tecovirimat SIGA TECHNOLOGIES INC. (US) 2018-07-24 US disclosed
US-10029985-B2 Methods of preparing Tecovirimat SIGA TECHNOLOGIES INC. (US) 2018-07-24 US disclosed
US-20180086705-A1 METHODS OF PREPARING TECOVIRIMAT SIGA TECHNOLOGIES, INC. (US) 2018-03-29 US disclosed
US-20180086705-A1 METHODS OF PREPARING TECOVIRIMAT SIGA TECHNOLOGIES, INC. (US) 2018-03-29 US disclosed
US-9889119-B2 Amorphous tecovirimat preparation SIGA TECHNOLOGIES, INC. (US) 2018-02-13 US disclosed
US-9889119-B2 Amorphous tecovirimat preparation SIGA TECHNOLOGIES, INC. (US) 2018-02-13 US disclosed
US-9862683-B2 Methods of preparing Tecovirimat SIGA TECHNOLOGIES, INC. (US) 2018-01-09 US disclosed
US-20170224661-A1 AMORPHOUS TECOVIRIMAT PREPARATION SIGA TECHNOLOGIES, INC. (US) 2017-08-10 US disclosed
US-20170224661-A1 AMORPHOUS TECOVIRIMAT PREPARATION SIGA TECHNOLOGIES, INC. (US) 2017-08-10 US disclosed
US-9670158-B2 Amorphous tecovirimat preparation SIGA TECHNOLOGIES, INC. (US) 2017-06-06 US disclosed
US-20170088517-A1 METHODS OF PREPARING TECOVIRIMAT SIGA TECHNOLOGIES, INC. (US) 2017-03-30 US disclosed
US-9546137-B2 Methods of preparing Tecovirimat SIGA TECHNOLOGIES INC. (US) 2017-01-17 US disclosed
US-9546137-B2 Methods of preparing Tecovirimat SIGA TECHNOLOGIES INC. (US) 2017-01-17 US disclosed
US-20160235676-A1 REHYDRATION OF MICRONIZED TECOVIRMIMAT MONOHYDRATE SIGA TECHNOLOGIES, INC. (US) 2016-08-18 US disclosed
US-20160152565-A1 AMORPHOUS TECOVIRIMAT PREPARATION SIGA TECHNOLOGIES, INC. (US) 2016-06-02 US disclosed
US-20160152565-A1 AMORPHOUS TECOVIRIMAT PREPARATION SIGA TECHNOLOGIES, INC. (US) 2016-06-02 US disclosed
US-20150322010-A1 METHODS OF PREPARING TECOVIRIMAT SIGA TECHNOLOGIES INC. (US) 2015-11-12 US disclosed
US-20150322010-A1 METHODS OF PREPARING TECOVIRIMAT SIGA TECHNOLOGIES INC. (US) 2015-11-12 US disclosed
US-8642577-B2 Compounds, compositions and methods for the treatment of poxvirus infections CHIMERIX, INC. (US) 2014-02-04 US disclosed
US-20070003516-A1 Compounds, compositions and methods for the treatment of poxvirus infections EMERGENT BIODEFENSE OPERATIONS LANSING LLC 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070003516-A1 Compounds, compositions and methods for the treatment of poxvirus infections IFNG, POLI, STING1 ALDH1A1 3014/4885SMN1; SMN2 3207/4885MEN1 4441/4885
US-20150322010-A1 METHODS OF PREPARING TECOVIRIMAT TYMP, NUDT1, HPRT1 ALDH1A1 2593/4885SMN1; SMN2 672/4885MEN1 3643/4885
US-20170224661-A1 AMORPHOUS TECOVIRIMAT PREPARATION TYMP, EIF4A3, TYMS ALDH1A1 2711/4885SMN1; SMN2 1630/4885MEN1 4818/4885
US-20170088517-A1 METHODS OF PREPARING TECOVIRIMAT TYMP, NUDT1, HPRT1 ALDH1A1 2593/4885SMN1; SMN2 672/4885MEN1 3643/4885
US-10029985-B2 Methods of preparing Tecovirimat TYMP, NUDT1, HPRT1 ALDH1A1 2593/4885SMN1; SMN2 672/4885MEN1 3643/4885
US-20160152565-A1 AMORPHOUS TECOVIRIMAT PREPARATION EIF4A3, TYMP, TENT4A ALDH1A1 1639/4885SMN1; SMN2 1939/4885MEN1 4868/4885
US-20180086705-A1 METHODS OF PREPARING TECOVIRIMAT TYMP, NUDT1, HPRT1 ALDH1A1 2593/4885SMN1; SMN2 672/4885MEN1 3643/4885
US-20160235676-A1 REHYDRATION OF MICRONIZED TECOVIRMIMAT MONOHYDRATE TSLP, CCL11, THPO ALDH1A1 3920/4885SMN1; SMN2 978/4885MEN1 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.